{"filings":[{"id":95780,"accession_number":"0001819790-26-000037","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q1 XDEMVY sales $145.4M (+85% YoY); net loss narrows to $7.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XDEMVY net product sales $145.4M vs $78.3M YoY; gross margin 94%.","Reaffirmed FY2026 XDEMVY guidance $670-700M; peak sales potential >$2B.","Net loss $7.0M ($0.16 loss per share) vs $25.1M loss ($0.64) YoY.","License fees $16.7M from $15M China regulatory milestone; cash $388.7M.","Phase 2 Calliope trial started for TP-05 Lyme disease prophylaxis; topline H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":162054000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109084,"accession_number":"0001819790-26-000017","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus reports FY2025 XDEMVY sales of $451.4M (+150% YoY); net loss narrows to $66.4M; guides peak >$2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net product sales $151.7M (Q4 2024: $66.4M); full-year $451.4M; ~400,000 bottles delivered in 2025.","Full-year net loss $66.4M ($1.59 loss per share) vs $115.6M ($3.07) in 2024; Q4 net loss $8.4M ($0.20) vs $23.1M ($0.60).","Management guided XDEMVY peak sales potential >$2B; gross margin held at 93%; cash $417.3M at year-end.","Initiated Phase 2 trial of TP-04 for ocular rosacea (topline 1H 2027); TP-05 Phase 2 for Lyme prevention expected Q2 2026.","David E.I. Pyott (former Allergan CEO) appointed to board; DTC campaign boosted patient awareness of Demodex blepharitis to ~25%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":451360000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109083,"accession_number":"0001819790-26-000005","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tarsus appoints former Allergan CEO David Pyott to Board of Directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pyott appointed as Class III director effective Feb 18, 2026; term expires at 2026 annual meeting.","He chairs Commercial Committee and serves on Nominating and Compensation Committees; deemed independent.","Initial equity grant target $540,000 (50% options, 50% RSUs) under non-employee director policy.","Pyott served as Allergan CEO for 17 years, grew revenue from ~$1B to >$7B; also on Alnylam and Pliant boards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109082,"accession_number":"0001819790-26-000002","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tarsus Pharmaceuticals furnishes corporate presentation; no material updates identified","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation published January 12, 2026, on company website.","Presentation highlights XDEMVY eye care product; no new financial or clinical data provided.","Routine Regulation FD disclosure; no guidance changes or strategic announcements.","Furnished excerpt does not contain specific numbers or events beyond product branding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125551,"accession_number":"0001819790-25-000120","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q3 2025: XDEMVY sales $118.7M, +147% YoY; net loss narrows to $0.30/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XDEMVY net sales of $118.7M (Q3 2024: $48.1M); >103,000 bottles delivered to patients.","Net loss of $12.6M vs $23.4M; diluted EPS $(0.30) vs $(0.61) in prior-year quarter.","Cash, equivalents & marketable securities of $401.8M as of Sept 30, 2025.","Phase 2 trial of TP-04 for ocular rosacea starting Dec 2025; Phase 2 of TP-05 for Lyme disease in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":299692000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142290,"accession_number":"0001819790-25-000107","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q2 net product sales $102.7M, up 152% YoY; net loss narrows to $20.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 net product sales $102.7M (+152% YoY); 91,000 bottles distributed.","Net loss $20.3M ($0.48 loss per share) vs $33.3M ($0.88) in Q2 2024.","Gross-to-net discount ~45%; DTC campaign drove 400% web engagement and 30% more prescribers.","Cash $381.1M; pipeline: Phase 2 TP-04 (ocular rosacea) H2 2025, TP-05 (Lyme) in 2026.","Global expansion: Japan regulatory meetings H2 2025; EU approval expected 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":180995000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160308,"accession_number":"0001819790-25-000100","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tarsus annual meeting: directors elected, say-on-pay approved, Ernst & Young ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Bobak Azamian, M.D., Ph.D. (20.8M for) and Katherine Goodrich, M.D. (26.8M for) as Class II directors.","Non-binding advisory vote approved named executive officer compensation: 27.1M for, 416,845 against, 16,635 abstain.","Stockholders selected an every-1-year frequency for future say-on-pay votes (26.9M votes for 1 year).","Ratification of Ernst & Young LLP as independent auditor for FY2025 approved: 34.7M for, 125,755 against, 7,803 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160307,"accession_number":"0001819790-25-000077","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q1 2025: XDEMVY sales $78.3M, up 217% YoY; net loss narrows to $25.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of XDEMVY $78.3M, up 217% vs Q1 2024 and 18% vs Q4 2024; ~72,000 bottles dispensed.","Net loss of $25.1M ($0.64 diluted loss per share), improved from $35.7M loss ($1.01 per share) in Q1 2024.","Cash, cash equivalents and marketable securities $407.9M as of March 31, 2025, bolstered by $134.8M equity offering.","SG&A expenses $85.0M, up from $51.6M, driven by DTC advertising and commercial expansion.","On track to initiate Phase 2 trial of TP-04 for Ocular Rosacea in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":78335000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178597,"accession_number":"0001819790-25-000035","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tarsus closes public offering of 3.23M shares; net proceeds $134.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised full over-allotment; total shares sold: 3,230,336 (incl. 421,348 additional shares).","Shares sold to underwriters at $41.83 each; public offering price $44.50.","Net proceeds of ~$134.8M after underwriting discounts and estimated offering expenses.","Offering closed on March 14, 2025; use of proceeds not specified but typical for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178596,"accession_number":"0001193125-25-053978","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tarsus prices upsized $125M public offering of 2.8M shares at $44.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,808,988 shares at public price $44.50; net proceeds ~$117.1M.","Upsized from originally proposed $100M; underwriters have 30-day option for additional 421,348 shares.","Closing expected March 14, 2025; Goldman Sachs, BofA, Barclays, Oppenheimer lead.","Offering made under effective shelf registration; use of proceeds not specified in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178595,"accession_number":"0001819790-25-000007","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q4 XDEMVY sales $66.4M; full-year $180.1M; net loss narrows to $0.60/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product sales $66.4M (vs $13.1M YoY); full-year $180.1M (vs $14.7M), with 163,000 bottles dispensed in 2024.","Net loss $23.1M ($0.60/share) in Q4 vs $41.9M ($1.31) in Q4 2023; full-year loss $115.6M ($3.07) vs $135.9M ($4.62).","Cash and marketable securities $291.4M as of Dec 31, 2024; gross-to-net discount ~45% on XDEMVY.","Pipeline: TP-04 for ocular rosacea on track to start Phase 2 in H2 2025; TP-05 for Lyme disease Phase 2 study planned.","Appointed Dr. Elizabeth Yeu as CMO and Dr. Katherine Goodrich to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":182953000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178594,"accession_number":"0001819790-25-000003","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tarsus board member Rosemary Crane resigns, becomes consultant; committee changes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rosemary Crane resigned from Board and committees effective Jan 17, 2025; not due to any disagreement.","Crane entered a 6-month consulting agreement with Tarsus, continuing to vest in equity awards.","Wendy Yarno appointed Chairperson of Commercial Committee; steps off Audit Committee effective Jan 17.","Andrew Goldberg, M.D. appointed to Audit Committee effective Jan 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178593,"accession_number":"0001193125-25-005030","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tarsus Pharmaceuticals posts corporate presentation on investor website","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Published January 13, 2025, on the Investor & News section of Tarsus website.","Presentation titled 'The Future of Eye Care Begins Here' filed as Exhibit 99.1.","No specific financial guidance, product updates, or material events disclosed.","Tarsus (NASDAQ: TARS) is focused on eye care, with XDEMVY as a key product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195262,"accession_number":"0001819790-24-000138","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Tarsus Pharmaceuticals signs 10-year lease for new HQ in Irvine, CA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 59,626 sq. ft. at 17700 Laguna Canyon Road, Irvine, CA; term 120 months.","Initial monthly base rent $211,672.30, with ~3% annual increases; 5-month rent abatement (~$656,756).","Construction allowance up to ~$6 million; security deposit via $2.56M letter of credit.","Lease commences ~11 months after signing or upon start of business activities at Premises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195261,"accession_number":"0001819790-24-000127","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q3 2024: XDEMVY sales $48.1M, net loss narrows to $23.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of $48.1M in Q3 2024, up from $1.7M in Q3 2023; over 41,400 bottles delivered.","Net loss of $23.4M ($0.61 per share) compared to $39.1M ($1.28 per share) in Q3 2023.","Secured the two remaining large Medicare contracts; coverage now extends to >80% of covered lives.","Appointed Elizabeth Yeu, M.D. as Chief Medical Officer and Katherine Goodrich, M.D. to board.","Cash and marketable securities of $317.0M as of September 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":116545000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195260,"accession_number":"0001819790-24-000119","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tarsus appoints Elizabeth Yeu as CMO; she resigns from board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Yeu appointed Chief Medical Officer effective Nov 4, 2024; resigned from Board same date.","Annual base salary of $480,000, $25,000 signing bonus, and 45% annual incentive bonus.","Granted 27,278 RSUs vesting 25% annually over four years, and option for 41,074 shares.","Severance includes 12 months salary and benefits; accelerated vesting on change in control.","Dr. Yeu previously served as board member since Dec 2021 and consulting Chief Medical Advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211517,"accession_number":"0001819790-24-000109","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q2 2024: XDEMVY net sales $40.8M (65% QoQ), net loss $33.3M, gross-to-net improves to 44%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XDEMVY net product sales $40.8M in Q2, up 65% over Q1; year-to-date $65.5M.","Gross-to-net discount improved to 44% from 55% in Q1; steady state expected low 40% in 2025.","More than 37,000 bottles delivered to patients in Q2; ~11,000 ECPs have started patients launch-to-date.","Net loss $33.3M (($0.88) per share) vs $31.4M in Q2 2023; SG&A $58.8M vs $20.3M due to launch costs.","Cash $323.6M including ~$39.6M from new credit facility draw; sales force expansion to ~50 additional reps by end of Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":68427000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230194,"accession_number":"0001819790-24-000087","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tarsus Pharma annual meeting elects two Class I directors, ratifies Ernst & Young auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bhaskar Chaudhuri (21.8M for, 2.9M withheld) and William Link (20.8M for, 3.9M withheld) elected as Class I directors.","Ratification of Ernst & Young as auditor for FY2024: 31.9M for, 24.9K against, 57.3K abstain.","Total shares voted: 31,978,938 out of 37,776,665 outstanding, quorum achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230193,"accession_number":"0001819790-24-000062","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q1 2024: XDEMVY sales $24.7M (+89% QoQ), net loss $35.7M, cash $298.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net product sales of XDEMVY $24.7M, up 89% from Q4 2023; ~26,000 bottles delivered (65% increase).","Net loss of $35.7M ($1.01 loss per share) vs $23.4M loss in Q1 2023.","SG&A expenses surged to $51.6M from $15.1M due to commercial launch costs.","Cash and marketable securities $298.5M as of Mar 31; secured $200M credit facility in Apr 2024 (drew $75M).","Secured commercial payer contracts covering ~18M lives on preferred status; broad coverage expected by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":27614000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230192,"accession_number":"0001819790-24-000050","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Tarsus secures $200M non-dilutive credit facility from Pharmakon; draws $75M initially","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $75M drawn April 19, 2024; used to repay Hercules Capital/SVB debt and for corporate purposes.","Additional $125M available in three tranches ($25M, $50M, $50M) through Dec 2025, subject to revenue milestones.","Interest at SOFR + 6.75% (3.75% floor); five-year interest-only, matures April 19, 2029.","No warrants or financial covenants; loan secured by substantially all assets.","Net proceeds ~$40M after repayment and fees; total committed capital from Pharmakon $200M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248622,"accession_number":"0001819790-24-000024","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tarsus Pharmaceuticals completes public offering, raising net proceeds of $107.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,281,250 shares and pre-funded warrants for 312,500 shares at $32.00 public price.","Underwriters exercised option in full to purchase additional 468,750 shares.","Net proceeds after discounts and expenses were approximately $107.8 million.","Offering closed March 5, 2024; led by Goldman Sachs, BofA Securities, Guggenheim Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248621,"accession_number":"0001193125-24-056209","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tarsus prices $100M public offering of common stock and pre-funded warrants at $32/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering consists of 2,812,500 shares common stock at $32.00/share and pre-funded warrants for 312,500 shares at $31.9999 each.","Underwriters granted 30-day option to purchase up to 468,750 additional shares at $32.00 less discounts.","Gross proceeds ~$100M; net proceeds expected ~$93.7M after discounts and expenses.","Offering expected to close March 5, 2024, subject to customary conditions.","Goldman Sachs, BofA, Guggenheim, and Oppenheimer are joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248620,"accession_number":"0001819790-24-000015","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q4 XDEMVY sales $13.1M; positive Phase 2a rosacea data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XDEMVY net product sales $13.1M in Q4, $14.7M total since late-August launch; >17,400 bottles dispensed.","Positive Phase 2a Galatea trial for TP-04 in papulopustular rosacea: statistically significant improvements in lesions and IGA score vs vehicle at Week 12.","Q4 net loss $41.9M ($1.31 EPS); full-year net loss $135.9M ($4.62 EPS).","Cash, equivalents and marketable securities $227.4M as of Dec 31, 2023.","~6,000 ECPs have started patients on XDEMVY; >50% prescribed to multiple patients as of Feb 23."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":17447000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}